Triptorelin

Triptorelin has Phase 3 RCT-grade clinical evidence for Prostate Cancer. Off-label / exploratory data exists for 51 additional indications (In Vitro Fertilization; Prostate Adenocarcinoma). 13 trials were withdrawn or terminated — surfaced below as signal of absence, not omitted.

Half-life~2.8 h

Data last updated

ClinicalResearchDepthClinicalResearchEfficacyClinicalResearchSideEffectsAnecdotalEfficacyAnecdotalSideEffectsPrice3.54.81.52.63.01.0

Research Evidence

Evidence shape

Triptorelin has Phase 3 RCT-grade clinical evidence for Prostate Cancer. Off-label / exploratory data exists for 51 additional indications (In Vitro Fertilization; Prostate Adenocarcinoma). 13 trials were withdrawn or terminated — surfaced below as signal of absence, not omitted.

Depthhow much
160 registered trials
74 completed · 27 with posted results · 26 recruiting / active · combined n=9566
Breadthhow many areas
65 indications mapped
12 with results · 51 thin / exploratory · 1 animal-only · 39 single-trial long-tail
Qualityhow rigorous
Highest tier: Phase 3
2 blinded with results · 46 distinct sponsors · AE rows aggregated from 17 trials · 45 linked publications on registered trials
Breadth and depth180 rows captured
Human
direct clinical signal
160
Animal
translational support
9
In vitro
mechanistic support
11
HighMediumLow

Anecdotal efficacy

Triptorelin side effects

Clinical research side effects

Anecdotal side effects

Price

Full buying guide →
1
Peptides Lab UK
UK
2 mg
$20.00
$10/mg
2
Peptides Lab UK
UK
2 mg
$26.85
$13.42/mg
3
peptidesourcehub.com
--
10 mg
$229.90
$22.99/mg
4
Huaian Hanyou Peptide
China
2 mg
$49.00
$24.5/mg
5
Cenexalabs
US
2 mg
$59.99
$30/mg
6
Adaptog Research
GB
10 mg
$370.46
$37.05/mg

price offers can be sorted by column

Triptorelin dosing & protocol

How Triptorelin is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials
Published clinical-trial protocols · n = 74
Typical dose
11.3 mg1 mg – 22.5 mg
typical
0
5 mg
10 mg
15 mg
20 mg
25 mg
distribution of 33 reported doses · darker = more
Frequency
daily
Route
subQ

Triptorelin was given subcutaneously daily, most often at about 11 mg, across a reported range of 1 mg to 22.5 mg; no cycling regimen was specified.

74 sources
Clinician practice
Doctor & published-protocol guidance · n = 1
Typical dose
100 µg
typical
0
5 mg
10 mg
15 mg
20 mg
25 mg
across 1 dosed source · darker = more agree
By reported cadence
Daily100 µg · n=1
Frequency
daily
Route
subQ

The sole source for this tier lists a fixed dose of 100 mcg administered subcutaneously on a daily basis; cycling information is not provided.

1 source
Anecdotal
Community-reported real-world use · n = 8
Typical dose
11.3 mg200 µg – 11.3 mg
typical
0
5 mg
10 mg
15 mg
20 mg
25 mg
distribution of 8 reported doses · darker = more
Frequency
unspecified
Route
subQ

Community reports most often use 11.25 mg of triptorelin, with a range from 200 mcg to 11.3 mg; dosing frequency was not specified in the majority of entries, though a few described administration every ~3 months.

8 sources

Regulatory safety notes

Warnings and precautions
  • • Hypersensitivity: Anaphylactic shock, hypersensitivity, and angioedema have been reported. In the event of a reaction, discontinue TRELSTAR and initiate appropriate medical management.
  • • Tumor Flare: Transient increase in serum testosterone levels can occur within the first few weeks of treatment. This may worsen prostate cancer and result in spinal cord compression and urinary tract obstruction. Monitor patients at risk and manage as appropr…
  • • Metabolic Syndrome: The use of GnRH agonists may lead to an increased risk of metabolic changes such as hyperglycemia, diabetes, hyperlipidemia, and non-alcoholic fatty liver disease. Monitor for signs and symptoms of metabolic syndrome including lipids, bloo…
  • • Cardiovascular Diseases: Increased risk of myocardial infarction, sudden cardiac death and stroke has been reported in men. Monitor for cardiovascular disease and manage according to current clinical practice.
  • • Convulsions: Convulsions have occurred in patients treated with GnRH analogs (including TRELSTAR) with or without a history of predisposing factors. Manage patients who experience convulsions according to institutional guidelines. Severe Cutaneous Adverse Rea…
  • • Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. Consider risks and benefits.
  • • Embryo-Fetal Toxicity: TRELSTAR may cause fetal harm. (5.10 , 8.1)
Contraindications
  • • Known hypersensitivity to triptorelin or any other component of the product, or other GnRH agonists or GnRH.
Drug interactions
  • • No drug-drug interaction studies involving TRELSTAR have been conducted. Human pharmacokinetic data with triptorelin suggest that C-terminal fragments produced by tissue degradation are either degraded completely within tissues, are rapidly degraded further i…

Related peptides

PT-141Kisspeptin-10HCGOxytocinGonadorelin